| Code | CSB-MP021369HU |
| Abbreviation | Recombinant Human SLAMF7 protein, partial (Active) |
| MSDS | |
| Size | $98 |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
SLAMF7 (CD319) is a self-ligand receptor expressed on natural killer cells, activated T cells, and multiple myeloma cells, making it a validated target for cancer immunotherapy and a key marker in hematologic malignancies. This mammalian-expressed extracellular domain (aa 23–226) exhibits a binding affinity of 0.18 nM to an anti-SLAMF7 monoclonal antibody as measured by surface plasmon resonance, demonstrating the conformational integrity required for therapeutic antibody epitope mapping, competitive inhibition screening, and receptor-ligand interaction studies. The protein supports use in functional ELISA with an EC50 of 8.9–10.3 ng/mL when immobilized at 2 μg/mL, providing quantitative benchmarks for blocking antibody validation and small-molecule inhibitor screening in oncology drug discovery. Endotoxin levels below 1.0 EU/μg and purity exceeding 95% meet the quality thresholds commonly required for SPR affinity characterization and biolayer interferometry assays in immune checkpoint research.
There are currently no reviews for this product.